

# Involvement of IncRNA IL21-AS1 in Interleukin-2 and T Follicular Regulatory Cell Activation in Systemic Lupus Erythematosus

**He Hao**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Shingo Nakayamada**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Naoaki Ohkubo**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Kaoru Yamagata**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Mingzeng Zhang**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Yu Shan**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Shigeru Iwata**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Tong Zhang**

University of Occupational and Environmental Health Japan: Sangyo Ika Daigaku

**Yoshiya Tanaka** (✉ [tanaka@med.uoeh-u.ac.jp](mailto:tanaka@med.uoeh-u.ac.jp))

University of Occupation and Environmental Health, Japan <https://orcid.org/0000-0002-0807-7139>

---

## Research article

**Keywords:** Systemic lupus erythematosus, Lymphocytes, T-cells, Molecular biology, Cytokines and inflammatory mediators

**Posted Date:** September 21st, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-885741/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Arthritis Research & Therapy on December 1st, 2021. See the published version at <https://doi.org/10.1186/s13075-021-02682-w>.

# Abstract

## Background

The single nucleotide polymorphism (SNP) rs62324212, located in IL21 antisense RNA 1 (IL21-AS1), has been identified as a genetic risk variant associated with systemic lupus erythematosus (SLE). We aimed to probe the characteristics of IL21-AS1 and explore its clinical relevance focusing T helper subsets and disease activity in patients with SLE.

## Methods

rs62324212 genotyping was determined using allelic discrimination by quantitative PCR. Gene expression in peripheral blood mononuclear cells and cell surface markers in CD4<sup>+</sup> T cells were analyzed using PCR and flow cytometry. The association among IL21-AS1, CD4<sup>+</sup> T cell subsets and SLE disease activity were assessed.

## Results

Ensembl Genome Browser analysis revealed that rs62324212 (C > A) was located in the predicting enhancer region of IL21-AS1. IL21-AS1 was expressed in the nucleus of CD4<sup>+</sup> T and B cells, but its expression was decreased in patients with SLE. IL21-AS1 expression was positively correlated with mRNA levels of IL-2 but not IL-21, and it was associated with the proportion of activated T follicular regulatory (Tfr) cells. Furthermore, we observed a significant negative correlation between IL21-AS1 expression and disease activity in patients with SLE ( $n = 53$ ,  $p < 0.05$ ).

## Conclusion

IL21-AS1 has an effect on disease activity through an impairment of IL-2-mediated activation of Tfr cell in SLE. Thus, targeting the IL21-AS1 may provide therapeutic approaches for SLE.

## Introduction

Systemic lupus erythematosus (SLE) is an immune-related disorder characterized by dysfunctional immune responses, leading to a lack of tolerance to self-antigens and over-secretion of autoantibodies. SLE mainly affects females of reproductive age, and nearly 50% of patients with SLE develop life-threatening complications, including nephritis, pulmonary hypertension, and central nervous system vasculitis (1, 2). Although an imbalance of CD4<sup>+</sup> T cell subsets is involved in the pathogenesis of SLE (3), the exact pathogenesis has not been elucidated yet. T follicular helper (Tfh) and T peripheral helper (Tph) cells induce B cell differentiation and autoantibody production whereas T regulatory and T follicular

regulatory (Tfr) cells inhibit B cell activation. The imbalance in T cell subsets has been postulated to be involved in the pathogenesis of SLE. Additionally, in SLE, IL-2 mediates the conversion of Tfh to Tfr cells through transcriptional regulation (4). Fine-tuning of the imbalance of Tfh and Tfr cells, would develop new treatment strategies, such as a low-dose IL-2 therapy, but the underlying mechanisms of this imbalance remain unclear.

A complex interaction of genetic, environmental, and hormonal factors is involved in SLE. Single nucleotide polymorphisms (SNPs) are primarily associated with SLE and other autoimmune diseases by altering the gene function and phenotype, and approximately 90% of SNPs are located in non-coding regions (5, 6). The genome wide-association studies (GWASs), which apply high-throughput genomic technologies, have identified many susceptible loci (7, 8), and several SLE-associated genes encoded at genetic risk loci, such as *IL-2*, *PDCD1*, *CTLA4*, and *IL-21*, are shown to be involved in the pathogenesis of SLE (9, 10).

The long non-coding RNA (lncRNA), a noncoding RNA containing more than 200 nucleotides, participates in gene regulation in many ways, such as condensing chromatin and chromosome through histone modifications, recruiting transcription factors and polysomes, and altering RNA splicing (11). LncRNAs participate in gene regulation through both cis (near the site of lncRNA) and trans (distant site from lncRNA) mechanisms (12). Recent studies have reported that lncRNAs, such as nuclear paraspeckle assembly transcript 1 (NEAT1), metastasis-associated lung adenocarcinoma transcript 1, and growth-arrest-specific transcript 5, are dysregulated in patients with SLE (13). The abnormal numbers of lncRNAs in the peripheral blood of patients with SLE can be used as potential biomarkers for diagnosis, determining therapeutic responses, and disease prognosis (14).

Interestingly, many disease-associated SNPs are located in the promoter, intron, or exon regions of lncRNAs, suggesting that SNPs may influence the expression levels of lncRNAs or alter their secondary structure, thereby affecting their regulatory functions (15). Many studies have revealed the correlation between SNPs in lncRNAs and cancer, autoimmune, and inflammatory diseases (16–20). Notably, a study using meta-analysis identified the SNP rs62324212 (C > A), located in IL21 antisense RNA 1 (IL21-AS1), residing just upstream of IL21 and IL-2 in all ten pediatric autoimmune diseases, including SLE (21). Moreover, IL-21 is required for the generation of Tfh cells and IL-2 is necessary for the development of Tfr cells (22, 4). However, the association among rs62324212, IL21-AS1, and SLE are poorly understood. The current study was designed to assess the characteristics of IL21-AS1 and explore the association among IL21-AS1 expression, cytokines, Th cells and lupus disease activity.

## Patients And Methods

### Patients

The study participants included 53 patients with SLE, 52 patients with rheumatoid arthritis (RA), who were diagnosed according to the American College of Rheumatology revised criteria, and 23 healthy

donors (HD). Disease activity was assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI). The clinical features of patients are listed in Table 1. The present study was approved by the Institutional Human Ethics Review Committee of the University of Occupational and Environmental Health, Japan, and it was performed according to the 1975 Declaration of Helsinki guidelines. All participants provided written informed consents prior to inclusion in the study. Details that might disclose the identity of subjects have been omitted.

Table 1  
Demographic and Clinical Characteristics of Study Subjects

	SLE (n = 53)	RA (n = 52)	HD (n = 23)
Age (year)	40.9 ± 17.8	64.3 ± 15.7	38.1 ± 8.0
Females, n (%)	49 (92.5)	35 (67.3)	20 (87.0)
Disease duration (month)	140.4 ± 159.9	83.6 ± 127.1	
SLEDAI score	4.9 ± 5.4		
BILAG score	4.8 ± 6.6		
Anti-dsDNA (U/ml)	34.4 ± 82.9		
IgG (mg/dl)	1657 ± 710.8	1374 ± 396.3	
CH50 (U/ml)	42.7 ± 14.1		
C3 (mg/dl)	84.7 ± 29.2		
C4 (mg/dl)	16.7 ± 9.1		
CRP (mg/dl)	0.2 ± 0.4	1.5 ± 2.0	
ESR (mm/hr)	36.0 ± 31.3	42.0 ± 28.1	
Prednisolone use at baseline, n (%)	36 (67.9)	18 (34.6)	
Dose of prednisolone (mg/day)	3.1 ± 3.3	3.8 ± 9.6	
Hydroxychloroquine use at baseline, n (%)	30 (56.6)		
Immunosuppressant use at baseline			
Mycophenolate mofetil, n (%)	10 (18.9)		
Calcineurin inhibitors, n (%)	9 (17.0)		
Azathioprine, n (%)	4 (7.5)		
Methotrexate, n (%)	2 (3.8)	36 (69.2)	
Mizoribine, n (%)	2 (3.8)		
Leflunomide, n (%)	1 (1.9)		

Data are mean ± SD or percentage of patients.

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BILAG: British Isle Lupus Assessment Group; Anti-dsDNA: Anti-double stranded DNA antibody; Anti-Sm: anti-smith antibody; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.

## Cell isolation

Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples using the lymphocyte separation medium (Cedarlane Corporation) according to manufacturer's instructions. Fresh PBMCs were suspended in 100 mL FACS solution (0.5% human albumin and 0.1% NaN<sub>3</sub> in PBS), and they were stained with the following monoclonal antibodies: anti-CD4-V500 (#560769), anti-CD8-PE-Cy<sup>™</sup>5.5 (#555368), anti-CD14-PE (#555398), and anti-CD19-FITC (#302206) (BD Biosciences). The stained CD4<sup>+</sup>CD8<sup>-</sup>CD14<sup>-</sup>CD19<sup>-</sup> T cells, CD4<sup>-</sup>CD8<sup>+</sup>CD14<sup>-</sup>CD19<sup>-</sup> T cells, CD4<sup>-</sup>CD8<sup>-</sup>CD14<sup>+</sup>CD19<sup>-</sup> monocytes, and CD4<sup>-</sup>CD8<sup>-</sup>CD14<sup>-</sup>CD19<sup>+</sup> B cells were incubated at 4 °C for 15 min, and they were sorted using the BD FACSAria II (BD Biosciences). The purity of sorted cells was always >95%.

## Flow cytometry

Fresh PBMCs from patients and healthy donors were washed and stained with the following antibodies at 4 °C for 15 min: anti-CD3-V450 (#560366, BD Biosciences), anti-CD4-V500 (#560769, BD Biosciences), anti-CD45RA-PE-Cy7 (#560675, BD Biosciences), anti-CXCR5-APC (#356907, BioLegend), and anti-PD-1-PE-Cy7 (#561272, BD Biosciences). For intracellular staining of anti-Foxp3-Alexa Fluor 488 (#560047, BD Biosciences), the cells were fixed and permeabilized with Transcription Factor Buffer at 4 °C for 30 min, and were washed with Perm/Wash Buffer (BD Biosciences) before intracellular staining. Isotype-matched control antibodies were used to monitor the background. The well-stained cells were subjected to flow cytometry using a BD FACSLyric system, and were further analyzed using the FlowJo v10 software (TOMY Digital Biology).

## Quantitative real-time PCR

Total RNA or cytoplasmic/nuclear RNA were extracted from cells using the RNeasy Mini Kit (Qiagen) or Cytoplasmic and Nuclear RNA Purification Kit (Norgen), respectively. Subsequently, RNAs were reverse transcribed into cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems). Quantitative PCR was performed using a sequence detection system with site-specific primers and probes. The expression level of *GAPDH* was detected as the endogenous control. The primers and probes, *IL21-AS1* (Hs04976181\_s1), *IFNG-AS1* (Hs04408308\_m1), *NEAT1* (Hs03453535\_s1), *IL2* (Hs00174114\_m1), *IL21* (Hs00222327\_m1), and *GAPDH* (Hs99999905\_m1), were purchased from Applied Biosystems. In addition, for the subcellular localization of *IL21-AS1*, RNA was extracted from the cytoplasmic and nuclear fractions of Jurkat and BJAB cells. Relative mRNA expression levels of *IL21-AS1* and *NEAT1* were evaluated using qPCR.

## Genotyping of SNPs

Genomic DNA was isolated from human PBMCs using Quick-DNA Miniprep Kit (#D3024, Zymo Research), and quantified using a NanoDrop spectrophotometer (NanoDrop Technologies). The genotypes of rs62324212 were determined using a specific TaqMan SNP genotyping probe (#4351379, Thermo Fisher) and TaqMan<sup>™</sup> Universal PCR Master Mix (#4324018, Thermo Fisher Scientific) according to manufacturer's protocol, and allelic discrimination was conducted using a quantitative real-time PCR system (Applied Biosystems).

## Statistical analysis

ANOVA was used to compare IL21-AS1 expression among the patients and controls. Differences between two groups were examined using the unpaired Student's *t*-test or Mann Whitney U test. Spearman's test was used for correlation analysis between two variables of interest. A *p*-value < 0.05 was considered statistically significant. All statistical tests were performed using GraphPad Prism software v8 (Prism Software, San Diego, CA, USA).

## Results

### Allele frequencies of rs62324212

The distribution of allele and genotype frequencies of rs62324212 was evaluated among healthy donors and patients with SLE and RA (Table 2). In patients with SLE, the A and C allele frequencies of rs62324212 were 36.8% and 63.2%, respectively, and the frequencies of three genotypes were 35.8% (CC), 54.7% (AC), and 9.5% (AA). Despite the small population size, the AA genotype frequencies in patients with SLE were slightly different (not significantly) to those observed in patients with RA (17.4%) and healthy donors (21.7%) and expected using the Ensembl genome database for a Japanese in Tokyo (20.2%) and East Asian population (18.1%). Generally, the minor alleles have led to a high tendency of being risk alleles for complex diseases due to an interplay of multiple genetic and environmental factors (23). The above results highlight the possibility that the minor allele [A] of rs62324212 may account for genetic susceptibility to SLE.

Table 2

Distribution of allele and genotype frequencies for rs62324212 among healthy donors, SLE and RA patients

	Group	n	Genotype n (%)			C allele (%)	A allele <sup>1)</sup> (%)
			CC	CA	AA		
Observed	HD	23	6 (26.1%)	12 (52.2%)	5 (21.7%)	52.2%	47.8%
	SLE	53	19 (35.8%)	29 (54.7%)	5 (9.5%)	63.2%	36.8%
	RA	52	15 (28.8%)	28 (53.8%)	9 (17.4%)	56.9%	43.1%
Expected <sup>2)</sup>	JPT <sup>3)</sup>	104	28 (26.9%)	55 (52.9%)	21 (20.2%)	53.4%	46.6%
	EAS <sup>4)</sup>	504	178 (35.3%)	235 (46.6%)	91 (18.1%)	58.6%	41.4%
1) The allele A belongs to the minor allele.							
2) <a href="https://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=4:122639284-122640284;v=rs62324212;vdb=variation;vf=72204332#373526_tablePanel">https://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=4:122639284-122640284;v=rs62324212;vdb=variation;vf=72204332#373526_tablePanel</a>							
3) JPT, Japanese in Tokyo							
4) East Asian							

### rs62324212 is located in the enhancer region of IL21-AS1

We examined the location of rs62324212 in the GWAS Catalog. The SNP rs62324212 was located within the lncRNA IL21-AS1, and the nearby genes were *IL21* and *IL2* (**Figure 1A**). The Ensembl Genome Browser analysis suggested that rs62324212 was located in the predicting enhancer region of IL21-AS1 (**Figure 1B**). The HaploReg analysis also indicated that rs62324212 resided in an open chromatin region with Histone H3 lysine K4 methylation 1 (H3K4me1) modifications. Since the function of the enhancer is highly cell type specific, it is important to have information on which cell type it matches with open chromatin. In HaploReg detail view, we found rs62324212 coincides with the enhancer region of CD4<sup>+</sup> T cells. The results of multiple bioinformatic tools indicated that rs62324212 might control IL21-AS1 transcription via regulation of enhancer activity.

### IL21-AS1 is associated with nuclear enrichment

Next, we examined the localization of IL21-AS1 by applying the Ensembl database. IL21-AS1, containing 70,173 bases and located at the chromosome band 4q27, was determined to be a novel antisense gene starting at 123540138 and ending at 123610311. Since the molecular functions of lncRNAs are dependent on proper subcellular localization, we analyzed IL21-AS1 localization in Jurkat and BJAB cells. We found that IL21-AS1 led to nuclear enrichment in Jurkat and BJAB cells, which suggested that IL21-AS1 may play functional roles in the nucleus (**Supplementary Figure 1**).

## Expression of IL21-AS1 is reduced in patients with SLE

We next evaluated the expression levels of three lncRNAs, including IL21-AS1 and IFNG Antisense RNA 1 (IFNG-AS1), in the PBMCs of HD and patients with RA and SLE. The expression of IL21-AS1 and NEAT1 in patients with SLE and RA were significantly lower as compared to that in HD (**Figure 2A**). IFNG-AS1 did not show any significant difference among the subjects (**Figure 2A**). PBMCs mainly comprised CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cell, B cells, and monocytes. We analyzed the expression of IL21-AS1 among the cells. IL21-AS1 levels were higher in CD4<sup>+</sup> T and B cells relative to those in CD8<sup>+</sup> T cells and monocytes (**Figure 2B**). This result was consistent with the published databases from DICE and GTEx which showed IL21-AS1 was highly expressed in CD4<sup>+</sup> T cells. Furthermore, IL21-AS1 expression in isolated CD4<sup>+</sup> T cells was significantly decreased in patients with SLE as compared to that in HD (**Figure 2C**).

## IL21-AS1 is associated with the expression of IL-2 and proportion of activated Tfr cells

IL-2 and IL-21 are the genes present near IL21-AS1. Therefore, we aimed to investigate whether IL21-AS1 influences IL-2 and IL-21 expression. We evaluated the gene expression levels of IL21-AS1, IL-2, and IL-21 from PBMCs in patients with SLE. IL21-AS1 was positively correlated with IL-2 gene level, but it did not show any significant correlation with IL-21 (**Figure 3A**).

Our recent study demonstrated that an imbalance of Tfr and Tfh cell activation is related to disease activity in patients with SLE, and IL-2 restores the balance between Tfh and Tfr cells through conversion of memory Tfh cells to functional Tfr cells (4). Therefore, we evaluated whether the observed IL21-AS1 defect in patients with SLE was associated with the proportion of Tfh and Tfr cells. The proportion of Tph cells (24, 25), which are involved in SLE pathogenesis, was also examined. CD4<sup>+</sup>CXCR5<sup>+</sup>Foxp3<sup>PD-1</sup><sup>hi</sup> Tph cells, CD4<sup>+</sup>CXCR5<sup>+</sup>Foxp3<sup>PD-1</sup><sup>hi</sup> Tfh cells, and CD4<sup>+</sup>CXCR5<sup>+</sup>Foxp3<sup>+</sup> Tfr cells along with their subsets were identified using flow cytometry (**Figure 3B**). Both Tph and PD-1<sup>hi</sup> Tfh cells did not show any significant correlation with IL21-AS1 (**Figure 3C**). For the Tfr cell subsets, CD45RA<sup>+</sup>Foxp3<sup>hi</sup>-activated Tfr (aTfr) cells exhibited a positive correlation with IL21-AS1 while CD45RA<sup>+</sup>Foxp3<sup>lo</sup> non-suppressive Tfr (ns-Tfr) and CD45RA<sup>+</sup>Foxp3<sup>lo</sup> resting Tfr (rTfr) cells did not (**Figure 3C**). Furthermore, IL21-AS1 was positively correlated with the activated Tfr/PD-1<sup>hi</sup> Tfh ratio (**Figure 3C**). Taken together, the above results suggest that IL21-AS1 may be involved in the production of activated Tfr cells.

## Relationship between IL21-AS1 and SLE activity

Finally, we explored the correlation of IL21-AS1 with disease activity, serum autoantibody, and inflammation markers in patients with SLE. We found a significant negative correlation between IL21-AS1 expression with SLEDAI or British Isles Lupus Assessment Group. Besides, IL21-AS1 expression was lower in anti-dsDNA-antibody positive patients than in negative ones (**Figure 4**).

## Discussion

After applying a combination of bioinformatic analysis and experimental approaches, we demonstrated frequencies of the minor allele [A] of rs62324212 in patients with SLE and that rs62324212 was located in the enhancer region of IL21-AS1. The expression of IL21-AS1 was decreased and correlated positively with expression of IL-2 gene and proportion of activated Tfr cells in patients with SLE. Furthermore, we found that IL21-AS1 was negatively correlated with disease activity of SLE, suggesting that a decreased expression of IL21-AS1 may promote SLE development.

Previously, two studies investigated the prominent role of SNPs in regulating the functions of lncRNAs in SLE. One study identified a new susceptibility locus in an lncRNA gene named SLEAR, which contains the polymorphism rs13259960 (A > G) (16). rs13259960 maps to an intronic enhancer of SLEAR, and the minor allele impairs the enhancer activity by suppressing the recruitment of STAT1 to the enhancer, resulting in reduced SLEAR levels. Moreover, SLEAR regulates apoptosis via interaction with interleukin enhancer binding factor 2, heterogeneous nuclear ribonucleoproteins F, and TATA-box binding protein associated factor 15 to construct a complex that regulates the transcription of anti-apoptotic genes. According to the other study, linc00513 expression is significantly upregulated in active patients than in inactive patients (17). Interestingly, two SNPs, rs205764 (T > G) and rs547311 (G > A), are present in the linc00513 promoter region, and the minor alleles increase the promoter transcriptional activity of linc00513, leading to an over-expression of linc00513 in patients with SLE (13). In this study, we demonstrated that rs62324212 (C > A) was present in the enhancer region, characterized by an open chromatin region with H3K4me1 modification of IL21-AS1, and the minor allele [A] reduced the expression of IL21-AS1. Since IL21-AS1 also decreased in patients with RA, we assessed the correlation between IL21-AS1 and disease activity in patients with RA. However, no significant correlation was observed between IL21-AS1 expression and disease activity scores such as Disease Activity Score with 28 joint (DAS28) using C-reactive protein (CRP) (DAS28-CRP) and DAS28 using erythrocyte sedimentation rate (ESR) (DAS28-ESR), CRP, ESR, and autoantibodies such as rheumatoid factor and anti-cyclic citrullinated peptide antibody (**Supplementary Fig. 2**). Therefore, the function of IL21-AS1 in RA requires further evaluation.

The genetic susceptibility locus of the *IL2/IL21* region at 4q27 has been previously reported in SLE and other autoimmune and inflammatory diseases (26–29). lncRNAs play regulatory roles through both cis and trans mechanisms. We found that IL21-AS1 is located near the *IL2/IL21* region, and IL21-AS1 was positively correlated with *IL2* gene level while IL21-AS1 did not show any significant correlation with *IL21*. Thus, IL21-AS1 may regulate IL2 production via the trans mechanism. However, the detailed mechanism of how IL21-AS1 mediates the generation of IL-2 requires further investigation.

Several studies have noted that lncRNAs are involved in immune cell differentiation and activation, which play an essential role in autoimmune diseases (30–32). For example, the increased expression of NEAT1, located in nucleus, contributes to the pathogenesis of SLE (33). Moreover, many lncRNAs exhibiting unique expression profiles in various CD4<sup>+</sup> T cell subsets, indicating that lncRNAs perform critical roles in CD4<sup>+</sup> T cell function during disease progression (34–37). From the Functional Annotation of the Mouse/Mammalian Genome database, we found that IL21-AS1 was highly expressed in normal human

lymph nodes, which included a large number of lymphocytes (**Supplementary Fig. 3**). From experimental data, we identified that the expression of IL21-AS1 was upregulated in CD4<sup>+</sup> T and B cells in human peripheral blood. Tfh, Tph, and Tfr cells belong to the CD4<sup>+</sup> T cell subset, and they play crucial roles in the pathogenesis of SLE (23, 24, 38, 39). IL21-AS1 showed a significant positive correlation with activated Tfr cells, which were decreased in active patients with SLE due to a defective IL-2 production (4), but not with PD-1<sup>hi</sup> Tfh and Tph cells. The results of this study along with those of our previous study suggest that IL21-AS1 may contribute to the regulation of IL-2 expression as a part of Tfr cell differentiation and function, providing possible mechanism for the role of lncRNAs in the regulation of various CD4<sup>+</sup> T cell subsets.

Our study had some limitations. For instance, according to the Ensembl Genome Browser and HaploReg analyses, rs62324212 is located in the enhancer region of IL21-AS1, but the accurate position still needs to be experimentally confirmed. Whether rs62324212 is directly responsible of the lower IL21-AS1 expression needs to explore further. It has been reported that lncRNAs are targets of the JAK-STAT signaling pathway during T helper cell differentiation (40). IL-2-activated STAT3 and STAT5 are critical for Tfr cell differentiation (4). Although our results indicate that IL21-AS1 is positively correlated with IL-2 levels and proportion of activated Tfr cells, the precise regulatory mechanism for IL21-AS1 and IL-2-Tfr cell axis requires further investigation. Moreover, larger sample sizes are needed in the future.

## Conclusion

In conclusion, our findings indicate that the possible involvement of IL21-AS1 in dysregulated IL-2-Tfr cell axis in patients with SLE. These findings highlight the vital roles of IL21-AS1 during disease progression in patients of SLE. Thus, IL21-AS1 can be treated as a therapeutic target for SLE.

## Abbreviations

IL-2  
Interleukin-2  
SNP  
Single nucleotide polymorphism  
IL21-AS1  
IL21 antisense RNA 1  
SLE  
Systemic lupus erythematosus  
Tfr  
T follicular regulatory  
Tfh  
T follicular helper  
Tph

T peripheral helper  
GWASs  
Genome wide-association studies  
lncRNA  
Long non-coding RNA  
NEAT1  
Nuclear paraspeckle assembly transcript 1  
RA  
Rheumatoid arthritis  
HD  
Healthy donors  
PBMC  
Peripheral blood mononuclear cells  
H3K4me1  
Histone H3 lysine K4 methylation 1  
IFNG-AS1  
IFNG Antisense RNA 1  
SELENA-SLEDAI  
Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus  
Disease Activity Index  
DAS28  
Disease Activity Score with 28 joint  
CRP  
C-reactive protein  
ESR  
Erythrocyte sedimentation rate

## **Declarations**

### **Acknowledgments**

The authors would like to thank the study participants, without whom this study could not be accomplished, as well as the investigators for their participation in the study, especially those in Kitakyushu General Hospital, Tobata General Hospital, Saiseikai Shimonoseki General Hospital, Fukuoka Yutaka Central Hospital, Nakama Municipal Hospital, and Steel Memorial Yahata Hospital. The authors thank the medical staff at the University of Occupational and Environmental Health, Japan for providing the data, especially Ms. Hiroko Yoshida, Ms. Youko Saitou, and Ms. Ayumi Maruyama for their excellent data management in the LOOPS registry and Ms. Narumi Sakaguchi, Ms. Kahoru Noda-Sugitani, and Ms. Megumi Hirahara for their excellent technical assistances.

### **Contributors**

H.H., S.N., and Y.T. designed the study; H.H. conducted the experiments, analyzed the data, and wrote the manuscript; N.O., K.Y., S.I., M.Z., Y.S., and T.Z. conducted the experiments; S.N. and Y.T. conceived the study concept and supervised the research and writing of the manuscript. All authors have reviewed and approved the final manuscript.

### **Ethical approval**

The present study was approved by the Institutional Human Ethics Review Committee of the University of Occupational and Environmental Health, Japan, and each subject provided a signed consent form (H29-045). The study was conducted in accordance with the Declaration of Helsinki guidelines. All participants provided informed consent prior to inclusion in the study. Details that might disclose the identity of study subjects have been omitted.

### **Data sharing statement**

No additional data is available.

### **Funding**

This work was supported by JSPS KAKENHI (grant numbers, JP19K08900 and JP20K08815) and the University of Occupational and Environmental Health, Japan through an UOEH Grant for Advanced Research (grant number H30-905).

### **Competing interests**

Dr. Nakayamada has received consulting fees, lecture fees, and/or honoraria from Bristol-Myers, GlaxoSmithKline, Chugai, Sanofi, Pfizer, Astellas, Asahi-kasei, Boehringer Ingelheim and has received research grants from Mitsubishi-Tanabe, Novartis, and MSD. Dr. Tanaka has received speaking fees and/or honoraria from Gilead, Abbvie, Behringer-Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers, Astra-Zeneca, received research grants from Asahi-Kasei, Abbvie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa, Behringer-Ingelheim, and consultant fee from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK, Abbvie. All other authors declare no conflicts of interest.

## **References**

1. Reid S, Alexsson A, Frodlund M, Morris D, Sandling JK, Bolin K, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. *Ann Rheum Dis.* 2020;79(3):363–9.
2. Ramos PS, Brown EE, Kimberly RP, Langefeld CD. Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis. *Semin Nephrol.* 2010;30(2):164–76.

3. Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. *Int J Rheum Dis*. 2020;23(4):465–71.
4. Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, et al. Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2020;73(1):132–42.
5. Shen LX, Basilion JP, Stanton VP. Jr. Single-nucleotide polymorphisms can cause different structural folds of mRNA. *Proc Natl Acad Sci U S A*. 1999;96(14):7871–6.
6. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. *Annu Rev Immunol*. 2009;27:363–91.
7. Iwamoto T, Niewold TB. Genetics of human lupus nephritis. *Clin Immunol*. 2017;185:32–9.
8. Bush WS, Moore JH. Chapter 11: Genome-wide association studies. *PLoS Comput Biol*. 2012;8(12):e1002822.
9. Hughes T, Kim-Howard X, Kelly JA, Kaufman KM, Langefeld CD, Ziegler J, et al. Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. *Arthritis Rheum*. 2011;63(6):1689–97.
10. Jd AS. C A, P SG, S C. Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations. *Curr Genomics*. 2014;15(1):52–65.
11. Fernandes JCR, Acuna SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long Non-Coding RNAs in the Regulation of Gene Expression: Physiology and Disease. *Noncoding RNA*. 2019;5(1).
12. Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding RNAs. *Trends Genet*. 2014;30(8):348–55.
13. Zhao CN, Mao YM, Liu LN, Li XM, Wang DG, Pan HF. Emerging role of lncRNAs in systemic lupus erythematosus. *Biomed Pharmacother*. 2018;106:584–92.
14. Taheri M, Eghtedarian R, Dinger ME, Ghafouri-Fard S. Exploring the Role of Non-Coding RNAs in the Pathophysiology of Systemic Lupus Erythematosus. *Biomolecules*. 2020;10(6).
15. Castellanos-Rubio A, Ghosh S. Disease-Associated SNPs in Inflammation-Related lncRNAs. *Front Immunol*. 2019;10:420.
16. Fan Z, Chen X, Liu L, Zhu C, Xu J, Yin X, et al. Association of the Polymorphism rs13259960 in SLEAR With Predisposition to Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2020;72(6):985–96.
17. Xue Z, Cui C, Liao Z, Xia S, Zhang P, Qin J, et al. Identification of lncRNA Linc00513 Containing Lupus-Associated Genetic Variants as a Novel Regulator of Interferon Signaling Pathway. *Front Immunol*. 2018;9:2967.
18. Wu J, Zhang TP, Zhao YL, Li BZ, Leng RX, Pan HF, et al. Decreased H19, GAS5, and linc0597 Expression and Association Analysis of Related Gene Polymorphisms in Rheumatoid Arthritis. *Biomolecules*. 2019;10(1).
19. Feng T, Feng N, Zhu T, Li Q, Zhang Q, Wang Y, et al. A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk. *J Exp Clin Cancer*


Res. 2020;39(1):157.

20. Tian J, Lou J, Cai Y, Rao M, Lu Z, Zhu Y, et al. Risk SNP-Mediated Enhancer-Promoter Interaction Drives Colorectal Cancer through Both FADS2 and AP002754.2. *Cancer Res.* 2020;80(9):1804–18.
21. Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. *Nat Med.* 2015;21(9):1018–27.
22. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *Immunity.* 2008 Jul 18;29(1):138–49.
23. Kido T, Sikora-Wohlfeld W, Kawashima M, Kikuchi S, Kamatani N, Patwardhan A, et al. Are minor alleles more likely to be risk alleles? *BMC Med Genomics.* 2018;11(1):3.
24. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, et al. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. *JCI Insight.* 2019;4(20).
25. Makiyama A, Chiba A, Noto D, Murayama G, Yamaji K, Tamura N, et al. Expanded circulating peripheral helper T cells in systemic lupus erythematosus: association with disease activity and B cell differentiation. *Rheumatology.* 2019;58(10):1861–9.
26. Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. *Ann Rheum Dis.* 2013;72(7):1233–8.
27. Maiti AK, Kim-Howard X, Viswanathan P, Guillen L, Rojas-Villarraga A, Deshmukh H, et al. Confirmation of an association between rs6822844 at the IL2-IL21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. *Arthritis Rheum.* 2010;62(2):323–9.
28. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. *Am J Hum Genet.* 2007;81(6):1284–8.
29. Jandl C, Liu SM, Canete PF, Warren J, Hughes WE, Vogelzang A, et al. IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2. *Nat Commun.* 2017;8:14647.
30. Hrdlickova B, Kumar V, Kanduri K, Zhernakova DV, Tripathi S, Karjalainen J, et al. Expression profiles of long non-coding RNAs located in autoimmune disease-associated regions reveal immune cell-type specificity. *Genome Med.* 2014;6(10):88.
31. Sigdel KR, Cheng A, Wang Y, Duan L, Zhang Y. The Emerging Functions of Long Noncoding RNA in Immune Cells: Autoimmune Diseases. *J Immunol Res.* 2015;2015:848790.
32. West KA, Lagos D. Long Non-Coding RNA Function in CD4(+) T Cells: What We Know and What Next? *Noncoding RNA.* 2019;5(3).
33. Zhang F, Wu L, Qian J, Qu B, Xia S, La T, et al. Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. *J Autoimmun.* 2016;75:96–104.


34. Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJ, Curti S, et al. The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. *Nat Immunol.* 2015;16(3):318–25.
35. Gibbons HR, Shaginurova G, Kim LC, Chapman N, Spurlock CF 3rd, Aune TM. Divergent lncRNA GATA3-AS1 Regulates GATA3 Transcription in T-Helper 2 Cells. *Front Immunol.* 2018;9:2512.
36. Brajic A, Franckaert D, Burton O, Bornschein S, Calvanese AL, Demeyer S, et al. The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells. *Front Immunol.* 2018;9:1989.
37. Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. *Int J Biol Macromol.* 2018;118(Pt A):24–30.
38. Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. *Eur J Immunol.* 2016;46(2):281–90.
39. Yang J, Yang X, Yang J, Li M. Baicalin ameliorates lupus autoimmunity by inhibiting differentiation of Tfh cells and inducing expansion of Tfr cells. *Cell Death Dis.* 2019;10(2):140.
40. Witte S, Muljo SA. Integrating non-coding RNAs in JAK-STAT regulatory networks. *JAKSTAT.* 2014;3(1):e28055.

## Figures

A




B



## Figure 1


rs62324212 is located in the enhancer region of *IL21-AS1* and the minor allele [A] reduces *IL21-AS1* expression (A) Representation of the single nucleotide polymorphism (SNP) rs62324212 (indicated by red dot) and nearby genes. (B) Location of rs62324212 (indicated by dotted line) using the Ensembl Genome Browser. RQ: relative quantity. CTCF: CCCTC-binding factor. Data symbols represent individual subjects; bars denote the mean  $\pm$  SEM. ns, not significant, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .



**Figure 2**

Downregulation of IL21-AS1 in patients with SLE (A) Relative mRNA expression of IL21-AS1, IFNG-AS1, and NEAT1 in isolated PBMCs from patients with SLE (n = 40), patients with RA (n = 35), and HD (n = 23), evaluated using qPCR. (B) Relative mRNA expression of IL21-AS1 in isolated monocytes, CD8+ T cell, CD4+ T cell, and B cells from HD (n = 5), evaluated using qPCR. (C) Relative mRNA expression of IL21-AS1 in isolated CD4+ T cells from HD (n = 8) and patients with SLE (n = 8), evaluated using qPCR. Data


symbols represent individual subjects; bars denote the mean  $\pm$  SEM. ns, not significant, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .



**Figure 3**

IL21-AS1 is positively associated with IL-2 expression and activated Tfr cells (A) The relative mRNA expression levels of IL21-AS1, IL2, and IL21 were analyzed in the isolated PBMCs of patients with SLE ( $n = 53$ ). Correlation of IL21-AS1 level with IL2 and IL21 in patients with SLE. (B-C) PBMCs were isolated

from the peripheral blood of patients with SLE (n = 29), and they were analyzed using flow cytometry without incubation and qPCR. (B) Gating strategy was employed to identify Tfh (CD4+CXCR5+Foxp3-), Tfr (CD4+CXCR5+Foxp3+), Tconv (CD4+CXCR5-Foxp3-), PD-1hi Tfh (CD4+CXCR5+Foxp3-PD-1hi), Tph (CD4+CXCR5-Foxp3-PD-1hi), rTfr (CD4+CXCR5+CD45RA+Foxp3lo), aTfr (CD4+CXCR5+CD45RA-Foxp3hi), and ns-Tfr (CD4+CXCR5+CD45RA-Foxp3lo) cells. (C) Correlation of IL21-AS1 level with the percentage of PD-1hi Tfh cell, Tph cell, Tfr cell subsets, and aTfr/PD-1hi Tfh ratio in patients with SLE (n = 29). Data symbols represent individual subjects; Spearman's test was used for correlation analysis between two variables of interest.



**Figure 4**

IL21-AS1 is negatively correlated with SLE activity The relative mRNA expression of IL21-AS1 in isolated PBMCs from patients with SLE (n = 53) was evaluated using qPCR. Correlation between IL21-AS1 expression levels and SLE Disease Activity Index, British Isle Lupus Assessment Group, C3 level, C4 level, CH50 level, C-reactive protein (CRP) level, IgG level, erythrocyte sedimentation rate (ESR) and comparisons of IL21-AS1 levels between patients with SLE classified as positive or negative for anti-

double-stranded DNA (anti-dsDNA) antibodies. Anti-dsDNA < 12 denotes a negative test (n = 39). Data symbols represent individual subjects. Spearman's test was used for correlation analysis between two variables of interest.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupFigure1.tif](#)
- [SupFigure2.tif](#)
- [SupFigure3.tif](#)